Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373094 | 0.83 | KDM4E (0.64) | KDM4EALDH1A1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL11277817 | 0.76 | TSHR (0.41) | KDM4EALDH1A1POLBHPGDGAA | |
| SCHEMBL3937400 | 0.74 | KDM4E (0.38) | KDM4EALDH1A1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL3937406 | 0.74 | KDM4E (0.41) | KDM4EALDH1A1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL3941669 | 0.74 | KDM4E (0.51) | KDM4EALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL3933310 | 0.72 | DRD2 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL27388836 | 0.69 | KDM4E (0.38) | KDM4EALDH1A1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL9475996 | 0.69 | KDM4E (0.48) | KDM4EALDH1A1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL5048134 | 0.69 | ALDH1A1 (0.42) | KDM4EALDH1A1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL27388776 | 0.68 | KDM4E (0.42) | KDM4EALDH1A1MAPTSMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | TEIJIN LIMITED (JP) | 2005-12-15 | — | — | US | disclosed |
| CN-1633436-A | Pyrrolopyrimidine derivatives | TEIJIN LTD (JP) | 2005-06-29 | — | — | CN | disclosed |
| EP-1477489-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | KDM4E 1378/4885ALDH1A1 2709/4885MAPT 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.